What is CellChorus?
CellChorus is at the forefront of dynamic single-cell analysis, leveraging its proprietary Time-lapse Imaging Microscopy in Nanowell Grids (TIMING) platform. This innovative system utilizes visual artificial intelligence to meticulously assess cell behavior across diverse environmental conditions. The technology empowers scientists to quantify the performance of thousands of immune cells, thereby accelerating clinical trial selection and deepening the understanding of clinical responses. By integrating motion and performance metrics with multiomic profiling, CellChorus delivers comprehensive insights into cellular function and intricate interactions. Its adaptable platform is designed for broad applicability across a wide spectrum of cell types and biological research endeavors.
How much funding has CellChorus raised?
CellChorus has raised a total of $2.5M across 1 funding round:
Grant
$2.5M
Grant (2024): $2.5M with participation from National Institutes of Health
Key Investors in CellChorus
National Institutes of Health
The National Institutes of Health (NIH) is a primary agency of the U.S. Department of Health and Human Services, dedicated to biomedical and health-related research, providing crucial support for scientific advancement.
What's next for CellChorus?
The substantial enterprise-level funding positions CellChorus for accelerated growth and innovation in the competitive biotech landscape. This strategic capital infusion is expected to fuel further development of its TIMING platform, enhance its AI capabilities for deeper cellular insights, and expand its market reach. The company's focus on providing granular data for clinical trials and biological research suggests a trajectory aimed at becoming an indispensable tool for pharmaceutical development and academic discovery. Future endeavors will likely involve forging strategic partnerships and scaling operations to meet the growing demand for advanced single-cell analytical solutions.
See full CellChorus company page
